Separate indirect from direct design evidence (SIDDE)

Fixed effects model: 

                   comparison k  nma direct indir. RoR z p-value
   BZD-intermediate:BZD-short 1 1.73   1.73      .   . .       .
 BZD-intermediate:eszopiclone 0 0.69      .   0.69   . .       .
     BZD-intermediate:placebo 1 0.77   0.70      .   . .       .
    BZD-intermediate:zaleplon 0 1.87      .   1.87   . .       .
    BZD-intermediate:zolpidem 1 0.85   0.97      .   . .       .
        BZD-short:eszopiclone 0 0.40      .   0.40   . .       .
            BZD-short:placebo 1 0.44   0.40      .   . .       .
           BZD-short:zaleplon 1 1.08   1.08      .   . .       .
           BZD-short:zolpidem 1 0.49   0.56      .   . .       .
          eszopiclone:placebo 3 1.12   1.12      .   . .       .
         eszopiclone:zaleplon 0 2.74      .   2.74   . .       .
         eszopiclone:zolpidem 0 1.25      .   1.25   . .       .
             zaleplon:placebo 0 0.41      .   0.41   . .       .
             zolpidem:placebo 3 0.90   0.90      .   . .       .
            zaleplon:zolpidem 0 0.46      .   0.46   . .       .

Legend:
 comparison - Treatment comparison
 k          - Number of studies providing direct evidence
 nma        - Estimated treatment effect (OR) in network meta-analysis
 direct     - Estimated treatment effect (OR) derived from direct evidence
 indir.     - Estimated treatment effect (OR) derived from indirect evidence
 RoR        - Ratio of Ratios (direct versus indirect)
 z          - z-value of test for disagreement (direct versus indirect)
 p-value    - p-value of test for disagreement (direct versus indirect)
[1] "Percent of comparisons where there is some evidence (p-value<0.05) of disagreement between direct and indirect sources: NaN. (0 out of 0 comparisons)."
[1] "File created on 2022-06-08"
